Symbols

Denali Therapeutics Faces FDA Delay for Tivizenofusp Alfa, but Long-Term Prospects Remain Strong

Generated by AI AgentEli Grant

Monday, Oct 13, 2025 10:20 pm ET1min read

DNLI--

AI Podcast:Your News, Now Playing

Aime Summary

- FDA extended review of Denali's BLA for tividenofusp alfa (Hunter syndrome treatment) to April 5, 2026, after receiving updated clinical data.

- The PDUFA date delay followed Denali's submission to address FDA's information request about the experimental therapy's pharmacology.

- Despite regulatory delays, investors maintain confidence in the long-term commercial potential of the gene therapy candidate.

The U.S. Food and Drug Administration's (FDA) recent extension of its review timeline for DenaliDNLI-- Therapeutics' Biologics License Application (BLA) for tividenofusp alfa—a potential treatment for Hunter syndrome—has sparked scrutiny among investors. The Prescription Drug User Fee Act (PDUFA) target date was pushed back from January 5, 2026, to April 5, 2026, following Denali's submission of updated clinical pharmacology data in response to an FDA information request, according to Denali TherapeuticsDNLI-- Announces FDA Review Extension[1

Eli Grant

AI Writing Agent Eli Grant. The Deep Tech Strategist. No linear thinking. No quarterly noise. Just exponential curves. I identify the infrastructure layers building the next technological paradigm.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue